Chronic myeloid leukemia (CML) is a type of blood cancer that begins in the blood-forming cells of the bone marrow.

It causes the uncontrolled production of abnormal myeloid cells, particularly white blood cells, which can interfere with the production of healthy blood cells.

At Bay Biosciences, we provide high-quality Chronic Myeloid Leukemia Samples, biopsy tissue, bone marrow aspirates, and matched serum, plasma, and peripheral blood mononuclear cells (PBMCs)  to support research on chronic myeloid leukemia.

Chronic Myeloid Leukemia samples

Understanding Chronic Myeloid Leukemia

Chronic myeloid leukemia develops in the blood-forming cells of the bone marrow, the soft tissue inside many bones where blood cells are produced.

CML causes the bone marrow to produce excessive numbers of abnormal white blood cells.

These cells can accumulate in the blood and bone marrow and interfere with the normal production of red blood cells and platelets.

Chronic myeloid leukemia is also called chronic myelogenous leukemia, chronic myelocytic leukemia, or chronic granulocytic leukemia.

Unlike acute leukemia, CML usually progresses more slowly.

However, without effective treatment, the disease can progress from the chronic phase to more advanced stages.

Symptoms of Chronic Myeloid Leukemia (CML)

Some patients with CML do not experience noticeable symptoms when the disease is first diagnosed.

Doctors may discover the condition during a routine blood test that shows an unusually high white blood cell count.

When symptoms develop, they may include:

These symptoms do not necessarily indicate CML because they can occur with other cancers and more common medical conditions.

Causes of Chronic Myeloid Leukemia (CML)

Researchers do not know exactly what causes the genetic change that leads to CML.

However, they understand that the disease develops when a translocation occurs between chromosomes 9 and 22. This creates the Philadelphia chromosome and the BCR-ABL1 fusion gene.

The BCR-ABL1 gene produces an abnormal protein that continuously activates signaling pathways involved in cell growth.

As a result, abnormal myeloid cells multiply excessively.

Unlike some inherited cancers, CML is generally not passed from parents to children. The genetic change usually develops randomly during a person’s lifetime

Diagnosis of Chronic Myeloid Leukemia (CML)

Doctors use several tests to diagnose and monitor CML

Blood Tests

A complete blood count (CBC) is commonly used to identify abnormal numbers of blood cells. Patients with CML often have a high white blood cell count. As the disease progresses, patients may also develop anemia or abnormal platelet levels.

Peripheral blood can therefore provide important Leukemia Blood Samples for diagnostic and research applications.

Bone Marrow Aspiration and Biopsy

A bone marrow aspiration removes a sample of liquid bone marrow, while a bone marrow biopsy removes a small piece of solid bone marrow tissue.

Pathologists examine these samples to evaluate blood-forming cells and identify abnormalities associated with CML.

Molecular Testing

Molecular testing looks for specific genetic abnormalities associated with CML.

The BCR-ABL1 fusion gene is a key molecular marker of CML. Testing for this gene can help confirm the diagnosis and monitor how well treatment is working.

Cytogenetic Testing

Cytogenetic testing examines chromosomes within cells.

For example, fluorescence in situ hybridization (FISH) can detect the BCR-ABL1 gene using blood or bone marrow cells. It can also help monitor disease during treatment.

These tests are particularly valuable for CML Biomarker Research, as researchers can investigate molecular changes associated with disease progression and treatment response.

Ultrasound

Ultrasound may be used to check for splenomegaly (an enlarged spleen), which is a common finding in CML. It’s not diagnostic on its own but helps assess disease burden and can be used to monitor spleen size during treatment.

Treatment and Management of CML

Treatment for CML has been transformed by tyrosine kinase inhibitors (TKIs), which target the BCR-ABL1 protein driving the disease.

First-Line Therapy

Imatinib, the first approved TKI, remains a strong first-line option, along with newer second-generation TKIs like dasatinib and nilotinib, which are often preferred for their faster, deeper responses.

Second- and Third-Line Options

Patients who are resistant or intolerant to first-line TKIs may switch to another TKI, such as bosutinib, ponatinib, or asciminib. Ponatinib is typically reserved for patients with the T315I mutation, which resists most other TKIs.

Advanced or Resistant Disease

For patients who don’t respond to multiple TKIs, options include switching therapy, combination approaches, or allogeneic stem cell transplantation, which remains a potential curative option for eligible patients.

CML Samples for Research

High-quality Chronic Myeloid Leukemia Samples are important resources for researchers studying the biology, progression, and treatment of CML.

CML Research Samples may support:

  • CML biomarker discovery and validation
  • Molecular profiling
  • Disease progression research
  • Treatment-response studies
  • Drug discovery and development
  • Drug resistance research
  • Hematology research
  • Diagnostic research

Frequently Asked Questions

What are CML Research Samples?

CML Research Samples are patient-derived biological specimens used in CML research, including blood, bone marrow, tissue, serum, plasma, and PBMCs.

What are Human CML Samples used for?

Human CML Samples are used for studying disease biology, biomarkers, treatment response, disease progression, and therapeutic development.

What are Leukemia Blood Samples used for?

Leukemia Blood Samples support research into leukemia cells, molecular biomarkers, treatment response, and disease characteristics.

What are Leukemia Biospecimens?

Leukemia Biospecimens are biological samples such as blood, bone marrow, tissue, plasma, and serum collected for leukemia research.

Can CML samples support CML Drug Development?

Yes. CML samples can support CML Drug Development by helping researchers evaluate drug response, resistance, therapeutic targets, and treatment mechanisms.

Supporting Your Research with Bay Biosciences

Bay Biosciences is a global provider of high-quality, clinical-grade, fully characterized human biospecimens and biological samples for biomedical and pharmaceutical research.

Our comprehensive collection of biospecimens includes:

If you have any questions, concerns, or special requests, please don’t hesitate to contact us.